Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis
- PMID: 26915744
- PMCID: PMC4869131
- DOI: 10.1038/eye.2016.18
Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis
Abstract
PurposeTo determine the opinions from a patient perspective on relevant variables in the delivery of treatment for neovascular age-related macular degeneration (nAMD).MethodsPilot interviews with patients and doctors were conducted to identify what variables in the provision of a nAMD service were important. This led to the generation of two sets of scenario options. Subsequently 100 patients undergoing active treatment for nAMD in the National Health Service University Hospital, United Kingdom underwent interview assessment. They were asked to rank their preferences for provision of their care with reference to these two sets of scenario options. Using conjoint analysis, percentage preferences, and utility scores for each variable in each scenario design were calculated.ResultsNinety-five patients completed the preference ranking for both scenarios. Eight patients ranked worse vision as preferable to better vision and were excluded on the basis that they had not understood the task. The results of the remaining 87 patients are presented. The most important factor to patients was having good vision, followed by a one-stop service and less frequent follow up. The least important factors were label status of the drug, cost to the health service, and grade of the injector.ConclusionPatients regard good vision and minimal visits to the hospital above the status of injector, label status of drug, or cost to the NHS.
Figures
Similar articles
-
Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis.Adv Ther. 2022 Oct;39(10):4808-4820. doi: 10.1007/s12325-022-02248-5. Epub 2022 Aug 22. Adv Ther. 2022. PMID: 35995894 Free PMC article. Review.
-
Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.Ophthalmology. 2016 Apr;123(4):876-83. doi: 10.1016/j.ophtha.2015.12.001. Epub 2016 Jan 14. Ophthalmology. 2016. PMID: 26778346 Clinical Trial.
-
Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.Acta Ophthalmol. 2016 Dec;94(8):e803. doi: 10.1111/aos.13153. Epub 2016 Jul 15. Acta Ophthalmol. 2016. PMID: 27417383 No abstract available.
-
TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.Retina. 2016 May;36(5):875-80. doi: 10.1097/IAE.0000000000000814. Retina. 2016. PMID: 26630316
-
Neovascular Age-Related Macular Degeneration.Dev Ophthalmol. 2016;55:125-36. doi: 10.1159/000438969. Epub 2015 Oct 26. Dev Ophthalmol. 2016. PMID: 26501146 Review.
Cited by
-
Methods to Assess Patient Preferences in Old Age Pharmacotherapy - A Systematic Review.Patient Prefer Adherence. 2020 Mar 4;14:467-497. doi: 10.2147/PPA.S236964. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32184575 Free PMC article. Review.
-
To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review.Ophthalmol Ther. 2025 Mar;14(3):489-514. doi: 10.1007/s40123-025-01093-3. Epub 2025 Feb 4. Ophthalmol Ther. 2025. PMID: 39904844 Free PMC article. Review.
-
Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis.Adv Ther. 2022 Oct;39(10):4808-4820. doi: 10.1007/s12325-022-02248-5. Epub 2022 Aug 22. Adv Ther. 2022. PMID: 35995894 Free PMC article. Review.
-
TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands.BMJ Open Ophthalmol. 2020 Dec 8;5(1):e000588. doi: 10.1136/bmjophth-2020-000588. eCollection 2020. BMJ Open Ophthalmol. 2020. PMID: 33344775 Free PMC article.
-
Patient and retina specialists' preferences in neovascular age-related macular degeneration treatment. A discrete choice experiment.PLoS One. 2021 Dec 31;16(12):e0261955. doi: 10.1371/journal.pone.0261955. eCollection 2021. PLoS One. 2021. PMID: 34972174 Free PMC article.
References
-
- Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444. - PubMed
-
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical